about
Pit2 assemblies at the cell surface are modulated by extracellular inorganic phosphate concentrationPatterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupRomiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopeniaRefractory thrombocytopenia and neutropenia: a diagnostic challenge.Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyConsolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot.Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.A French National Survey on Clotting Disorders in Mastocytosis.Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.Mitochondria in hematopoiesis and hematological diseases.ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance.A CASE OF CHORIORETINOPATHY AS FIRST MANIFESTATION OF HODGKIN'S LYMPHOMA.Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.Docosahexaenoic Acid Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells.Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: a single-centre prospective study assessing PCR-based diagnosis.Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.Primary solitary plasmacytoma of the liver - successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report.Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.Prospective assessment of FilmArray® technology for the rapid identification of yeast isolated from blood cultures.Rituximab for Sjögren syndrome-associated type II mixed cryoglobulinemic cerebral vasculitis.Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
P50
Q24673772-A8A60BFA-C89B-483E-9E0F-86E290CDB76BQ31150088-BC09BEF5-3369-481A-9D62-4B2273C56795Q33388563-0606C5EC-6105-413F-80E1-36F9F2837D15Q33396652-CF9456E7-E298-4CE0-B8B1-71B659C26B87Q33399582-6C00247F-370F-4DA6-8F61-513424864DBEQ33404104-05086885-B17B-4ABC-893D-AB3EDB59EAE5Q33405891-BE45376F-FFEC-4191-A082-C53642B25BD5Q33406127-759F4B4F-3AF5-4876-828E-02BBA24B439FQ33420934-EA001624-49C6-4129-A9C5-FDEF146BAE27Q33425610-C96D9CE0-161C-4BAB-9277-C5C6652FD1E1Q33434137-08538B38-8D93-46A9-937D-EFDDFDCF5589Q33437608-AC75C5F9-78D4-4544-9724-29B1FB6BE70FQ33437640-2E317D6D-EA2E-4A60-BFF3-4F185FF05A79Q34065294-D1DDA44E-6749-422A-92A5-5D0DD9F6847DQ34711661-E4B90159-A756-4A39-B715-35B678F5B832Q34918221-1CAADBF8-FE0C-44F2-A105-262BAFC4660CQ35143466-51323E54-A212-4453-B877-9A70C19B4C6EQ36150869-A2EEFCB7-D272-407C-996F-C5312663640FQ36195456-AF9FEC90-156B-41D1-AD1D-BA566CFAC6BAQ36234396-A79BFC8B-5DF4-4320-8808-43814D5CB0C8Q36337603-7E655764-817B-4863-A709-FB8E5C07AF77Q36558011-53F377A5-72BB-4CBE-B096-0CF3492BF3D9Q37499442-BA50CEF1-FF36-413B-8250-DB74F7D009C2Q37989067-232CC145-4225-4E79-AACE-F6EF12ACC797Q39005626-4CB44C2F-03CD-4466-BB45-15EAA88993ABQ39448829-6FC1778C-917B-4769-B50D-B0FA223B1278Q39578940-8AF89061-4C19-44D5-A64C-33E74500B095Q39730021-1B10D495-3C97-418A-AF50-FD29053DEFE3Q39745836-050795F0-5D65-4B64-AA14-D420E33A7AA1Q40122568-A044FA6C-F9BD-4EA0-B0D9-FEC7E9A91CE6Q40392537-67458A7F-A3D9-489E-9FA0-224FD6644B88Q40844110-6400AC3D-737F-4ABA-BB7A-E3B2927C981EQ40846213-BBC171A2-F953-40D1-8DFE-C2BDA9F951E9Q40863791-D65D6EDE-1D27-48F2-9779-3940E60B1330Q41041217-481EE1CA-F1B6-4A59-8712-854CFA24C92CQ41139081-5DF197DD-790A-4AD7-ADB9-CCD4368686C6Q41206138-CF816725-B012-481F-BE7D-B1739DEE7254Q41752212-2680F9AF-8006-4F4F-BF68-9169E0C034ADQ42413961-185A261B-0EAB-461A-B9E5-3C7722C5D45BQ43431147-79318674-0D05-47BF-99D2-2E6282B41B9A
P50
description
researcher ORCID ID = 0000-0002-7651-9189
@en
wetenschapper
@nl
name
Emmanuel Gyan
@ast
Emmanuel Gyan
@en
Emmanuel Gyan
@es
Emmanuel Gyan
@nl
type
label
Emmanuel Gyan
@ast
Emmanuel Gyan
@en
Emmanuel Gyan
@es
Emmanuel Gyan
@nl
prefLabel
Emmanuel Gyan
@ast
Emmanuel Gyan
@en
Emmanuel Gyan
@es
Emmanuel Gyan
@nl
P1153
6505818989
P31
P496
0000-0002-7651-9189